MarketCap
Facebook
X
Telegram
Teladoc Health Balance Sheet 2025-2011 | TDOC
Brief overview of Teladoc Health's assets and capital
The balance sheet is assessed across five available annual reports spanning 2018 to 2025.
Over the period, assets gained +87%, moving from $1.5 billion to $2.9 billion. CAGR near 9.4% shows consistent growth.
Liabilities grew faster than assets: +185.5% versus +87%. A substantial part of expansion was externally funded.
The equity ratio is 48.5% versus 66.3% five periods ago. Capitalization remains workable.
Net debt equals roughly 0.16x of equity. This is a moderate load and leaves room for maneuver.
The cash share moved from 27.7% to 27.3%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -$16.4 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
Taken together, the figures indicate acceptable resilience for Teladoc Health. The next assessment depends on debt and equity trends.
Annual Balance Sheet Teladoc Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
225 M | -297 M | 426 M | 631 M | 345 M | 658 M | -71.2 M | 45.2 M | 244 M | -5.59 M | -28.6 M | -20.4 M | -212 K | - | - |
Long Term Debt |
995 M | 991 M | 1.54 B | 1.54 B | 1.23 B | 1.38 B | 440 M | 415 M | 207 M | 42.4 M | 25.2 M | 25.2 M | 3 M | - | - |
Long Term Debt Current |
11 M | 10.3 M | 10.8 M | 13.6 M | 12.7 M | 11.4 M | 5.09 M | - | - | 2 M | 1.25 M | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 499 M | 453 M | 225 M | 51.7 M | 33.2 M | 25.8 M | 3.19 M | - | - |
Total Current Liabilities |
405 M | 942 M | 421 M | 400 M | 331 M | 333 M | 90.2 M | 62.4 M | 40.3 M | 21.1 M | 18 M | - | - | - | - |
Total Liabilities |
1.47 B | 2.03 B | 2.07 B | - | - | - | 589 M | 516 M | 265 M | 72.8 M | 51.2 M | 38.8 M | 8.33 M | - | - |
Deferred Revenue |
62.3 M | 79.3 M | 95.7 M | 90.5 M | 75.6 M | 65.8 M | 12.5 M | 7.65 M | 4.11 M | 1 M | 831 K | - | - | - | - |
Retained Earnings |
-16.4 B | -16.2 B | -15.2 B | -15 B | -1.42 B | -993 M | -508 M | -409 M | -312 M | -205 M | -131 M | -72.5 M | -55.5 M | - | - |
Total Assets |
2.86 B | 3.52 B | 4.39 B | 4.35 B | 17.7 B | 17.8 B | 1.6 B | 1.53 B | 824 M | 304 M | 230 M | 92 M | 27.4 M | - | - |
Cash and Cash Equivalents |
781 M | 1.3 B | 1.12 B | 918 M | 893 M | 733 M | 514 M | 424 M | 42.8 M | 50 M | 55.1 M | 46.4 M | 3.21 M | - | - |
Book Value |
1.39 B | 1.49 B | 2.33 B | 4.35 B | 17.7 B | 17.8 B | 1.01 B | 1.01 B | 559 M | 231 M | 179 M | 53.2 M | 19.1 M | - | - |
Total Shareholders Equity |
1.39 B | 1.49 B | 2.33 B | 2.31 B | 16 B | 15.9 B | 1.01 B | 1.01 B | 559 M | 231 M | 179 M | -67.5 M | -55.5 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Teladoc Health
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 996 M | 994 M | 993 M | 992 M | 991 M | 991 M | 990 M | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.54 B | 1.53 B | - | 1.53 B | 1.23 B | 1.21 B | 1.2 B | 1.35 B | 1.38 B | 1.38 B | 1.38 B | 1.38 B | 440 M | 440 M | 440 M | 440 M | 415 M | 415 M | 415 M | 415 M | 207 M | 207 M | 207 M | 42.4 M | 42.4 M | 42.5 M | 27.1 M | 42.4 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | 25 M | 25.2 M | 25.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.45 B | 1.47 B | 1.49 B | 1.47 B | 2.02 B | 2.03 B | 2.02 B | 2.02 B | - | 2.07 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
60.8 M | 65.7 M | 70.1 M | 74.7 M | 73.9 M | 79.3 M | 88.3 M | 95.4 M | 101 M | 95.7 M | 99.2 M | 107 M | 95.9 M | 102 M | 90.2 M | - | 83.8 M | 75.6 M | 72.9 M | 69.3 M | 70.5 M | 52.4 M | 52.4 M | 52.4 M | 52.4 M | 12.5 M | 12.5 M | 12.3 M | 12.5 M | 7.65 M | 7.65 M | 7.65 M | 7.65 M | 4.11 M | 3.52 M | 2.41 M | 1.62 M | 1 M | 1 M | 1 M | 1 M | 831 K | 831 K | 831 K | 831 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-16.5 B | -16.5 B | -16.4 B | -16.4 B | -16.3 B | -16.2 B | -16.2 B | -16.1 B | -15.3 B | -15.2 B | -15.2 B | -15.1 B | -15.1 B | -15 B | -11.2 B | - | -8.02 B | -1.42 B | -1.41 B | -1.33 B | -1.19 B | -993 M | -993 M | -993 M | -993 M | -508 M | -508 M | -508 M | -508 M | -409 M | -409 M | -409 M | -409 M | -312 M | -312 M | -312 M | -312 M | -205 M | -205 M | -205 M | -205 M | -131 M | -131 M | -131 M | -131 M | -72.5 M | -72.5 M | -72.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.76 B | 2.81 B | 2.88 B | 2.89 B | 3.44 B | 3.52 B | 3.53 B | 3.52 B | 4.32 B | 4.39 B | 4.33 B | 4.32 B | 4.31 B | 4.35 B | 8.1 B | - | 11.1 B | 17.7 B | 17.7 B | 17.6 B | 17.6 B | 17.8 B | 17.8 B | 17.8 B | 17.8 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.53 B | 1.53 B | 1.53 B | 1.53 B | 824 M | 824 M | 824 M | 824 M | 304 M | 304 M | 304 M | 304 M | 230 M | 230 M | 230 M | 230 M | 91.8 M | 92 M | 92 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
774 M | 751 M | 726 M | 680 M | 1.19 B | 1.3 B | 1.24 B | 1.16 B | 1.1 B | 1.12 B | 1.03 B | 959 M | 889 M | 918 M | 900 M | 881 M | 836 M | 893 M | 824 M | 784 M | 720 M | 733 M | 733 M | 733 M | 733 M | 514 M | 514 M | 514 M | 514 M | 424 M | 424 M | 424 M | 424 M | 42.8 M | 42.8 M | 42.8 M | 42.8 M | 50 M | 50 M | 50 M | 50 M | 55.1 M | 55.1 M | 55.1 M | 55.1 M | 46.4 M | 46.4 M | 46.4 M | - | 3.21 M | - | - | - | 8.69 M | - | - | - | - | - | - | - |
Book Value |
1.31 B | 1.34 B | 1.39 B | 1.42 B | 1.43 B | 1.49 B | 1.51 B | 1.5 B | 4.32 B | 2.33 B | 4.33 B | 4.32 B | 4.31 B | 4.35 B | 8.1 B | - | 11.1 B | 17.7 B | 17.7 B | 17.6 B | 17.6 B | 17.8 B | 17.8 B | 17.8 B | 17.8 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.53 B | 1.53 B | 1.53 B | 1.53 B | 824 M | 824 M | 824 M | 824 M | 304 M | 304 M | 304 M | 304 M | 230 M | 230 M | 230 M | 230 M | 91.8 M | 92 M | 92 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.31 B | 1.34 B | 1.39 B | 1.42 B | 1.43 B | 1.49 B | 1.51 B | 1.5 B | 2.29 B | 2.33 B | 2.29 B | 2.3 B | 2.29 B | 2.31 B | 6.05 B | 6.08 B | 9.14 B | 16 B | 16 B | 16 B | 15.8 B | 15.9 B | 15.9 B | 15.9 B | 15.9 B | 1.01 B | 1.01 B | 1.01 B | 1.01 B | 1.01 B | 1.01 B | 1.01 B | 1.01 B | 559 M | 559 M | 559 M | 559 M | 231 M | 231 M | 231 M | 231 M | 179 M | 179 M | 179 M | 179 M | -67.5 M | -67.5 M | -67.5 M | - | -55.5 M | - | - | - | -46.5 M | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Teladoc Health, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B |  USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
So-Young International
SY
|
$ 1.84 | 0.55 % | $ 143 M |  China |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 100.61 | -0.38 % | $ 8.67 B | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Zhongchao
ZCMD
|
$ 1.13 | -11.72 % | $ 3.86 M | China |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
American Well Corporation
AMWL
|
$ 10.75 | -0.83 % | $ 173 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 6.05 | -3.51 % | $ 112 M | USA |
 |
Progyny
PGNY
|
$ 31.13 | -1.14 % | $ 2.65 B | USA |
 |
Phreesia
PHR
|
$ 10.73 | 1.13 % | $ 641 M | USA |
 |
GoodRx Holdings
GDRX
|
$ 3.07 | -3.15 % | $ 1.09 B | USA |
 |
Schrödinger
SDGR
|
$ 15.14 | -1.37 % | $ 1.11 B | USA |
 |
Omnicell
OMCL
|
$ 35.37 | -4.69 % | $ 1.63 B | USA |
 |
Health Catalyst
HCAT
|
$ 2.09 | 0.48 % | $ 146 M | USA |
 |
HealthStream
HSTM
|
$ 28.04 | -0.57 % | $ 842 M | USA |
 |
Evolent Health
EVH
|
$ 3.09 | -2.83 % | $ 353 M | USA |
 |
10x Genomics
TXG
|
$ 47.27 | -4.37 % | $ 5.9 B | USA |
 |
Veeva Systems
VEEV
|
$ 203.78 | 1.1 % | $ 33.4 B | USA |